v3.26.1
Segment Reporting
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting

14. Segment Reporting

The Company operates and manages its business as one reportable segment and one operating segment, which is dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated medicines that address significant health problems and that meaningfully improve patients’ lives. The Company’s chief operating decision maker, or CODM, is the chief executive officer. The CODM assesses performance for the segment and decides how to allocate resources based on consolidated net loss that is also reported on the consolidated statements of operations.

The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. All material long-lived assets are located in the United States. Long-lived assets consist of property and equipment, net, and operating lease right-of-use assets.

The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.

Factors used in determining the reportable segment include the nature of the Company’s operating activities, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance. The accounting policies of the segment are the same as those described in Note 2 of the notes to the consolidated financial statements included in the Company's Annual Report on Form 10-K.

The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:

 

 

Three Months Ended
March 31,

 

 

2026

 

2025

 

Revenue

$

34,365

 

$

22,100

 

Less:

 

 

 

 

   Research and development expenses

 

 

 

 

       External research and development:

 

 

 

 

            STAT6

 

33,211

 

 

20,605

 

            Other external research and development expense (1)

 

24,962

 

 

26,378

 

       Research and development compensation and related personnel expense (2)

 

27,939

 

 

22,049

 

       Research and development overhead and administrative costs

 

12,050

 

 

11,223

 

  General & administrative (3)

 

20,357

 

 

16,271

 

  Interest and other expense

 

61

 

 

72

 

Plus:

 

 

 

 

  Interest income

 

14,981

 

 

8,917

 

Segment net loss

$

(69,234

)

$

(65,581

)

 

(1) Certain prior period amounts have been recast to conform with current period presentation.

(2) Research and development compensation and related personnel expense for the quarter ended March 31, 2026 and 2025 is inclusive of $8.6 million and $7.5 million of stock-based compensation expense, respectively.

(3) General and administrative expense for the quarter ended March 31, 2026 and 2025 is inclusive of $7.4 million and $6.7 million of stock-based compensation expense, respectively.

 

Depreciation expense for the three months ended March 31, 2026 and 2025 was $1.6 million and $1.6 million respectively. Amortization expense related to right-of-use assets for the three months ended March 31, 2026 and 2025 was $0.4 million and $0.4 million respectively.